Barr initiates patent challenge
27 September 2007 00:00 in Pharmaceutical Company Product News
Barr Pharmaceuticals has initiated a challenge on the patents listed by Sanofi-Avenits over its Uroxatral (alfuzosin hydrochloride extended-release tablets), 10mg.
The subsidiary of Barr Laboratories has disclosed that its Abbreviated New Drug Application (ANDA) contains a paragraph IV certification for a generic Uroxatral product and that it was approved by US Food and Drug Administration (FDA) in June of this year.
Barr was then prevented from proceeding with the marketing of the product after Sanofi-Aventis filed a suit in the district of Delaware.
Barr claims that its ANDA had been accepted for filing and that it notified the New Drug Application (NDA) and patent holder.
However under the Hatch-Waxman Act, the action taken by Sanofi-Aventis formally initiates the patent challenge while Barr has formally acknowledged that other companies have filed an ANDA for alfuzosin hydrochloride extended-release tablets, and have been sued
Earlier this year, Barr Pharmaceuticals saw the resignation of its chief operating officer Paul M Bisaro, who was also the board member for newly acquired Pliva.
Other news stories from 27/09/2007
Read more in the Zenopa News Archive
How this news is generated
Story collated for Zenopa by the Adfero News Agency